OptiNose, Inc. – NASDAQ:OPTN
OptiNose stock price today
$9.6
+9.20
+2347.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
OptiNose stock price monthly change
-69.13%
month
OptiNose stock price quarterly change
-69.13%
quarter
OptiNose stock price yearly change
-71.18%
year
OptiNose key metrics
Market Cap | 60.37M |
Enterprise value | 202.71M |
P/E | -2.44 |
EV/Sales | 2.65 |
EV/EBITDA | -3.52 |
Price/Sales | 2.17 |
Price/Book | -2.92 |
PEG ratio | -0.06 |
EPS | -0.26 |
Revenue | 74.02M |
EBITDA | -16.24M |
Income | -30.70M |
Revenue Q/Q | 25.61% |
Revenue Y/Y | 0.89% |
Profit margin | -98.11% |
Oper. margin | -73.28% |
Gross margin | 87.86% |
EBIT margin | -73.28% |
EBITDA margin | -21.95% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOptiNose stock price history
OptiNose stock forecast
OptiNose financial statements
Average Price Target
$1
Potential downside: -89.58%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 19.45M | 2.62M | 13.5% |
|---|---|---|---|
| Sep 2023 | 19.82M | -9.29M | -46.88% |
| Dec 2023 | 19.86M | -9.96M | -50.17% |
| Mar 2024 | 14.88M | -14.06M | -94.54% |
| Jun 2023 | 106068000 | 175.72M | 165.67% |
|---|---|---|---|
| Sep 2023 | 101407000 | 179.02M | 176.54% |
| Dec 2023 | 107729000 | 194.33M | 180.39% |
| Mar 2024 | 83707000 | 182.92M | 218.53% |
| Jun 2023 | -12.53M | -79K | -1K |
|---|---|---|---|
| Sep 2023 | -4.42M | -176K | 135K |
| Dec 2023 | 6.90M | -73K | 4K |
| Mar 2024 | -22.02M | -22K | 7K |
OptiNose alternative data
| Aug 2023 | 141 |
|---|---|
| Sep 2023 | 141 |
| Oct 2023 | 141 |
| Nov 2023 | 141 |
| Dec 2023 | 141 |
| Jan 2024 | 141 |
| Feb 2024 | 141 |
| Mar 2024 | 132 |
| Apr 2024 | 132 |
| May 2024 | 132 |
| Jun 2024 | 132 |
| Jul 2024 | 132 |
OptiNose other data
57.93%
+3.44%
of OPTN is owned by hedge funds
32.93M
+3.87M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 52875 |
| Mar 2024 | 0 | 36602 |
| Jun 2024 | 0 | 25824 |
| Jul 2024 | 0 | 167679 |
| Sep 2024 | 0 | 8107 |
| Dec 2024 | 0 | 7664 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | MARINO MICHAEL F III officer: Chief Le.. | Common Stock | 3,050 | $0.44 | $1,342 | ||
Sale | MAHMOUD RAMY A director, officer.. | Common Stock | 4,614 | $0.44 | $2,030 | ||
Sale | MARINO MICHAEL F III officer: Chief Le.. | Common Stock | 3,226 | $0.87 | $2,807 | ||
Sale | MAHMOUD RAMY A director, officer.. | Common Stock | 4,881 | $0.87 | $4,246 | ||
Sale | KRICK ANTHONY J officer: Chief Accounting Officer | Common Stock | 6,845 | $1.14 | $7,803 | ||
Sale | MARINO MICHAEL F III officer: Chief Le.. | Common Stock | 49,408 | $1.14 | $56,325 | ||
Sale | MAHMOUD RAMY A director, officer.. | Common Stock | 111,426 | $1.14 | $127,026 | ||
Sale | MARINO MICHAEL F III officer: Chief Le.. | Common Stock | 3,267 | $1.19 | $3,888 | ||
Sale | MAHMOUD RAMY A director, officer.. | Common Stock | 18,987 | $1.19 | $22,595 | ||
Sale | KRICK ANTHONY J officer: Chief Accounting Officer | Common Stock | 624 | $1.19 | $743 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of OptiNose stock today?
One share of OptiNose stock can currently be purchased for approximately $9.6.
-
When is OptiNose's next earnings date?
Unfortunately, OptiNose's (OPTN) next earnings date is currently unknown.
-
Does OptiNose pay dividends?
No, OptiNose does not pay dividends.
-
How much money does OptiNose make?
OptiNose has a market capitalization of 60.37M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 6.93% to 70.99M US dollars.
-
What is OptiNose's stock symbol?
OptiNose, Inc. is traded on the NASDAQ under the ticker symbol "OPTN".
-
What is OptiNose's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of OptiNose?
Shares of OptiNose can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are OptiNose's key executives?
OptiNose's management team includes the following people:
- Mr. Peter K. Miller Chief Executive Officer & Director(age: 64, pay: $999,810)
- Dr. Ramy A. Mahmoud M.D., M.P.H. Pres & Chief Operating Officer(age: 60, pay: $737,550)
- Mr. Michael F. Marino Chief Legal Officer & Corporation Sec.(age: 49, pay: $604,710)
- Mr. Keith Alan Goldan Chief Financial Officer(age: 54, pay: $600,210)
- Mr. Victor M. Clavelli Chief Commercial Officer(age: 52, pay: $584,200)
-
How many employees does OptiNose have?
As Jul 2024, OptiNose employs 132 workers.
-
When OptiNose went public?
OptiNose, Inc. is publicly traded company for more then 7 years since IPO on 13 Oct 2017.
-
What is OptiNose's official website?
The official website for OptiNose is optinose.com.
-
Where are OptiNose's headquarters?
OptiNose is headquartered at 1020 Stony Hill Road, Yardley, PA.
-
How can i contact OptiNose?
OptiNose's mailing address is 1020 Stony Hill Road, Yardley, PA and company can be reached via phone at +267 364 3500.
-
What is OptiNose stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for OptiNose in the last 12 months, the avarage price target is $1. The average price target represents a -89.58% change from the last price of $9.6.
OptiNose company profile:
OptiNose, Inc.
optinose.comExchange:
NASDAQ
Full time employees:
132
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
1020 Stony Hill Road
Yardley, PA 19067
Yardley, PA 19067
CIK: 0001494650
ISIN: US68404V1008
CUSIP: 68404V100
